Cofactor Genomics Valuation Estimate
Cofactor Genomics Valuation as of Last Funding Round
Cofactor Genomics Company Overview
Cofactor Genomics is a biotechnology company that leverages RNA-expression models to bring precision medicine to immunotherapy. The company develops predictive diagnostics that characterize the microenvironment of a tumor and predict patient response to immunotherapy. Cofactor Genomics was founded following the Human Genome Project and focuses on creating multidimensional biomarkers to better match patients to therapies. The company is involved in the PREDAPT Trial, which evaluates the use of its OncoPrism assay to predict responses to immunotherapy across various solid tumor cancers
Cofactor Genomics Valuation History
FAQ
Does Cofactor Genomics have stock?
Yes, Cofactor Genomics and almost all privately held companies issue stock so founders, employees, and investors can participate in equity ownership. However, because Cofactor Genomics is privately held, it is more challenging to acquire shares than if the company was publicly traded.
Is Cofactor Genomics publicly traded?
No, Cofactor Genomics is a privately held company. It is not publicly traded or offered directly on any stock exchange like the NYSE, Nasdaq, etc.
Who owns Cofactor Genomics stock?
As a privately held company, Cofactor Genomics shares are held by its founders, management, employees, venture capital funds, or other private individuals and institutional investors.
Disclosure rules differ for private and public companies, so it may not always be possible to know the complete ownership (cap table) of a private company like Cofactor Genomics.
What is the stock symbol for Cofactor Genomics?
Cofactor Genomics is a privately held company. Therefore, it does not have a stock symbol or “ticker” that trades on public exchanges like the NYSE, Nasdaq, etc.
Can I buy Cofactor Genomics stock on UpMarket?
If you would like to buy shares in Cofactor Genomics, please provide your information in the form at the top of this page and click the button titled “I want to buy this stock.”
One of our investor relations team members will contact you to discuss Cofactor Genomics stock availability. Note: inquiries are non-binding, subject to market availability, and shares may only be purchased by accredited investors that meet all eligibility criteria.
UpMarket has offered many similar companies as Pre-IPO investments, including Airbnb, SpaceX, ByteDance, Plaid, Kraken, Databricks, and others. UpMarket also often has funds available that invest in a portfolio of companies potentially including, Cofactor Genomics as well.
What is Cofactor Genomics stock price?
The stock price of Cofactor Genomics can be calculated by taking the valuation of the company divided by the number of shares outstanding. Because a private company can issue new shares at any time, we do not know the current number of shares outstanding.
For illustrative purposes, however, assuming Cofactor Genomics has issued 250 million shares, at the estimated UpMarket valuation of $35.27 million, each share of Cofactor Genomics stock would be worth $0.14.
How do Cofactor Genomics pre-IPO trades work?
Pre-IPO trades for Cofactor Genomics will typically involve accredited investors purchasing shares from current shareholders through specialized investment platforms like UpMarket. Trades generally occur on the secondary market, meaning Cofactor Genomics doesn't issue new shares or receive capital–shares are privately exchanged between two parties.
While investors aim to profit from a potential IPO or acquisition, these investments carry high risks due to limited liquidity and information. Understanding all terms and conditions is crucial, as each transaction can have unique characteristics. Investing in private companies can be extremely risky and may result in significant capital loss.
When is Cofactor Genomics going to go public?
The decision to go public through an Initial Public Offering (IPO) is complex and depends on various factors, including the company's financial performance, market conditions, and strategic goals.
Unless Cofactor Genomics officially announces its intention to go public, any predictions about when or if it will do so would be speculative.
Investors interested in Cofactor Genomics should monitor official company communications and reliable financial news sources for any updates regarding potential IPO plans.
How do I exit my investment if I invest in Cofactor Genomics with UpMarket?
Exiting your investment in Cofactor Genomics typically involves one of these scenarios: 1) selling your shares on a secondary market to other interested investors; 2) holding shares until a liquidity event occurs, such as the company going public (IPO) or being acquired.
Investors must know that the timing and availability of these exit options are inherently unpredictable, and there is no guarantee of when or if they will occur.
How can I sell Cofactor Genomics shares?
If you own Cofactor Genomics shares, you may be able to find a buyer on a pre-IPO marketplace or via an introduction by a registered broker-dealer like UpMarket. It is important to note that the class of shares you own may impact your ability to sell. For example, shares issued to startup employees often have transaction limitations, including lock-up periods and a right of first refusal by the company, which may prevent you from selling your shares freely.
How does UpMarket estimate the valuation of Cofactor Genomics?
UpMarket’s valuation estimate for Cofactor Genomics is algorithmically generated based on recent primary round financings by Cofactor Genomics, market conditions, company popularity, sector performance, and public market comps.
It is important to note that UpMarket’s valuation estimate for Cofactor Genomics could be outdated, may not reflect all recent news or market events, and is not intended to inform any investment decision-making. UpMarket’s valuation estimate is not meant to be a warranty or projection of potential financial returns or company performance. Valuations can change rapidly and unexpectedly.
Why choose UpMarket?
UpMarket was founded in 2019 and has helped hundreds of investors access alternative investments. UpMarket is a licensed broker-dealer based in the United States. UpMarket customers have invested over $150 million in pre-IPO companies, hedge funds, private equity, real estate, and other alternatives.
If you are an accredited investor, you can create a free account to access our deal flow and opportunities. There is never any pressure to invest.
UpMarket clients have invested in companies like
Cofactor Genomics,
SpaceX, Neuralink, Anthropic, and many others. UpMarket and its leadership have been mentioned in media outlets like Forbes, WealthManagement, Wealth and Finance News, and TechBullion.
Cofactor Genomics Management
| Name | Position |
|---|---|
| JARRET GLASSCOCK | CEO |
| DAVE MESSINA | COO |
